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Plasma prorenin as an early marker of nephropathy in diabetic
(111DM) adolescents. We studied a group of 50 adolescents, average age
16 years, with diagnosed IDDM present for about seven years. Twenty-five
had microalbuminuria (MA) averaging 111.0 34.0 (saM) j.tg/min albu-
min excretion rate versus 6.7 7.4 .tg/min in the 25 without MA. In other
respects, such as sex ratio, age, body mass index, duration of IDDM,
hemoglobin Ale, and normotensive systolic, diastolic and mean blood
pressures (BP), these subgroups were closely matched, We compared
them with a control group of 39 normotensive adolescents, of whom 18
were carefully matched siblings of the IDDM subjects with MA and 21
were similarly matched siblings of the IDDM non-MA subjects. Plasma
renin concentration was determined by a direct radioimmunoassay
method (Sanofi-Pasteur) and found to be virtually the same in the control
and IDDM adolescents as a whole. There was also no real difference
between the MA and non-MA subgroups. In contrast, plasma prorenin
was significantly higher in the combined IDDM group (197.5 9.3 vs.
control, 134.0 7.9 pg/mI, P < 0.0001). It was also higher in the MA
subgroup than in the non-MA subgroup (226.4 13.6 vs. 1683 10.1
pg/mI, P c 0.001). Interestingly, the 18 control siblings matching the MA
subgroup had higher plasma prorenin than the 21 control siblings match-
ing the non-MA subgroup (P C 0.001), suggesting a familial predisposition
that precedes detectable diabetes and nephropathy. Our findings confirm
and extend reports by other workers that elevated plasma prorenin is
associated with incipient nephropathy, manifested by MA. The exclusive
renal origin of this prorenin, its role in plasma, and the mechanism
responsible for its elevation in 111DM with MA, are yet to be demon-
strated, as is the general applicability of these findings to different
populations of diabetics, with a higher incidence and severity of compli-
cations.
High levels of inactive renin, usually called prorenin, circulate
in the blood of normal humans, that is, about 90% of 'total plasma
renin' which represents the sum of active and inactive renin [1, 2].
The physiological or pathophysiological significance of altered
levels of this prorenin is not well understood, especially in relation
to diabetes mellitus.
Day, Leutscher and Gonzales [3] first reported a high concen-
tration of 'big renin' (prorenin) in the plasma of diabetic patients
with renal disease. Such patients also had low plasma renin
activity. Bryer-Ash, Ammon and Leutscher [4] reported signifi-
cantly elevated levels of inactive renin in diabetic patients without
overt complications of diabetes, which rose even higher in patients
with detectable nephropathy. These observations favor the view of
plasma prorenin as an early marker of progressive diabetic
nephropathy but provide no explanation as to the mechanisms
responsible. Such a marker would have obvious importance in
pinpointing diabetic subjects who might benefit from more ag-
gressive medical treatment aimed at delaying target organ dam-
age.
Not all observations support this attractive 'marker' concept.
Fujii et al [5] did not find elevated plasma prorenin concentrations
in diabetic subjects displaying obvious nephropathy or retinopa-
thy. In Type II diabetics, Trujillo et al [6] observed no real rise in
plasma prorcnin and no difference between normotcnsivc and
hypertensive patients, the latter being more susceptible to renal
disease and eventual nephropathy. More explicitly, Franken et al
[7] suggested that "independent of the presence, or absence, of
microalbuminuria, the mean plasma level of prorenin was not
above normal in patients without retinopathy and was 2 to 3 times
normal in patients with proliferative retinopathy." They proposed
that high plasma prorenin levels are related to the general
development of microvascular disease and may be partly, even
mainly, attributable to an increased production and release from
extrarenal sources, including the eyes, and/or to decreased clear-
ance from the circulation.
Thus, virtually all pertinent issues concerning plasma prorenin
in diabetes—elevated level, renal origin, association with early
nephropathy—remain unsetttled. This might be expected when
data are compared from diverse populations of diabetic patients
and different experimental protocols and laboratory methods.
The aim of this study was to re-examine the question of plasma
prorenin as a marker of early (incipient) nephropathy, using
microalbuminuria (MA) as the indicator. We studied a carefully
defined group of adolescents diagnosed with insulin dependent
diabetes mellitus (IDDM) with and without MA. The controls
were well-matched, non-diabetic siblings. Prorenin and renin were
determined by a well-validated, sensitive, direct prorenin/renin
immunoassay technique [8—10].
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Methods
Subjects
The adolescent subjects were drawn from a population attend-
ing the Diabetes Clinic at The Hospital for Sick Children, Toronto.
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Using a one-hour timed urine collection [11], we screened 265
adolescents, aged 12 to 18 years, with insulin dependent diabetes
mellitus (IDDM) of more than two years duration. The presence
of incipient nephropathy was determined by the detection of
microalbuminuria (MA) in the one-hour urine collection and in at
least one of two subsequent 24-hour urine collections. For pur-
poses of this study, MA was defined as an albumin excretion rate
(AER) greater than 15 zg/min, and we identified 25 adolescents
in this category. Each was matched with respect to age, sex,
duration of IDDM, and body mass index (BMI) to an IDDM
adolescent without MA (non-MA). We also studied 39 apparently
healthy siblings of the IDDM subjects. In cases where more than
one such sibling was available, the one most closely matching each
IDDM adolescent, for age and BMI, was chosen. The patients
received no medication other than insulin and thyroxine replace-
ment, if hypothyroid, while none of the siblings received any
medication at all.
Microalbuminuria
Urine samples were quickly stored at —20°C and analyzed
within three months of collection. A double antibody radioim-
munoassay (Pharmacia AB, Uppsala, Sweden) validated in our
laboratory [11] was used to determine albumin concentration.
Blood pressure
Subjects sat quietly for at least five minutes prior to BP
measurement in their right arm. We used the automated Dinamap
Vital Signs Monitor (Critikon, Tampa, Florida, USA) to make at
least three BP measurements, two minutes apart. The mean BP
values reported here were calculated from the last two systolic and
diastolic pressure readings that fell within 5 mm Hg of each other.
Hemoglobin Aic (HbAlc)
HbAlc was measured by high performance liquid chromatog-
raphy (HPLC) after removal of the labile fraction [12]. The
reference range for non-diabetics was 4 to 6% HbAlc. The "current"
HbAlc was taken to represent the value during the study period,
while the "mean" HbAlc represented the mean of values deter-
mined during routine clinic visits (every 3 to 4 months) subsequent
to the date of diagnosis of diabetes.
Renin, prorenin and 'total renin'
Renin, that is, active renin, represents the renin activity origi-
nally present in the plasma. Prorenin represents the inactive
precursor that we activate to renin in vitro, using exogenous
trypsin. 'Total renin' represents the original active renin plus the
additional renin formed by tryptic activation of prorenin. Thus,
subtraction of 'active' from 'total' renin provides the given esti-
mates of 'prorenin.' All determinations were carried out 'blind' in
coded tubes.
Tryptic activation of prorenin
We used well-established techniques [13—161 with further re-
finements outlined herein. The trypsin was from bovine pancreas
(type III, T-8253, lot no. 16F-0249; Sigma, St. Louis, Missouri,
USA), extinction coefficient 14.4 at 280 nm in a 1% solution. The
enzyme was dissolved in 0.002 N analytical grade HCI in distilled
water and made up into a stock solution containing 10.0 mg/mi,
quantitated by absorbance at 280 nm. This solution, 10 tl, was
added to 100 1.d plasma, final concentration 1 mg trypsin/mi, and
incubated for 18 h at 4°C. The reaction was terminated by adding
10 1d of soybean trypsin inhibitor (SBTI, type IS, T-9003, lot no.
40H8200, Sigma) from a stock solution of 10 mg/ml in 0.02 M Tris
acetate buffer, pH 7.4. We used 18 hours of incubation at 4°C to
conform more closely to the activation method of Derkx et al [17].
We confirmed in a few test samples that the data obtained were
comparably good to those we get by using much shorter incuba-
tion intervals at 37°C, depending on the concentration of tiypsin
used, as also reported by Derkx et al [17].
Active renin
Active renin was determined prior to activation of prorenin but
with built-in reagent controls to match the conditions of tryptic
activation. In essence, trypsin in the selected concentration (see
above) was first inactivated by incubating it with the SBTI stock
solution, 1:1 vol/vol, for 10 mm at 23°C. The resulting inactivated
mixture was added to the control plasma at 20 1d/100 1d. We
confirmed that this step did not produce detectable activation of
prorenin by comparing renin values obtained from several such
reagent control samples with those obtained from control plasmas
to which trypsin neutralized by SBTI had not been added.
Direct radioimmunoassay of renin
The direct renin kit [10] was used according to the accompa-
nying instructions. The results were validated against convention-
ally obtained plasma renin activity (PRA) values, based on
radioimmunoassay of angiotensin I [18]. We have demonstrated
[18] very good agreement (correlation coefficient 0.9401) between
the direct renin assay (pg/mi) and conventional PRA (ng/mllhr)
across a PRA range of about 2 to 27 ng Ang I/mI plasma/hr, in
both unactivated and activated human plasmas, which range is
applicable to the present data.
Other procedures for active and total renin
Both active and total renin were determined in duplicate,
working with two sets of 2 aliquots of 100 pA of the prepared
plasmas. Our procedure was according to the directions given in
the direct renin kit. The tubes were shaken during the incubation
steps: two and three hours for the first and second antibody
reactions, respectively. All standards and unknown samples were
assayed in duplicate. The standard curves were plotted to express
bound counts as a percentage of total counts, relative to renin
concentration in pg/mi. Linear regression analysis was used to
construct the standard curve of best fit.
Statistical analysis
The results, expressed as means SEM, were assessed by
Student t-tests for paired and unpaired means and by linear
regression analysis where applicable.
Results
IDDM adolescents with (MA) and without microalbuminuria
(non-MA) and controls
The IDDM adolescents, MA and non-MA subgoups, were well
matched for age, sex, duration of IDDM, body mass index (BMI)
and HbA1C (mean and "current," Table 1). Systolic and diastolic
BPs in the two subgroups were similar and in the low normoten-
sive range, but there was a trend towards slightly higher values in
the MA group.
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MA
N=5 Non-MAN=25
Sex, M:F 14:11 12:13
Age, years
Body mass index, kg/rn2
16.0 0.4
23.4 0.5
15.9 0.3
23.2 0.5
Duration of IDDM, years 7.2 0.8 7.2 0.5
HbAlc mean, % 9.2 0.3 8.5 0.2
HbAlc current, % 9.1 0.4 8.6 0.3
AER, pg/mm 111.0 34.0" 6.7 0.74
Systolic blood pressure, mm Hg 107.0 2.2 104.0 2.0
Diastolic blood pressure, mm Hg 59.0 1.2 56.0 1.2
Mean arterial pressure, mm Hg 75.0 1.5 73.0 1.4
Active renin, pg/mi 40.0 4.6 33,6 4.7
Prorenin, pg/mI 226.4 13.6c 168.5 10.1
IDDM
N=50 SiblingsN=39
Sex, M'F 26:24 18:21
Age, years 15.9 0.2 19.1 0.8
Body mass index, kg/m2 23.0 0.4 22.0 0.6
HbAlc mean, % 8.8 0.2 a
HbAlc current, % 9.0 o.2' 4.9 0.04
Duration of IDDM, years 7.2 0.5 N/A
Systolic blood pressure, mm Hg 106.0 1.4 102,0 1.3
Diastolic blood pressure, mm Hg 57.0 0.8 56.0 1.0
Mean arterial pressure, mm Hg 74.0 1.0 71.0 1.0
Active renin, pg/mi
Prorenin, pg/mi
36.8 3.3
197.5 9.3"
35.6 1.9
134.0 7.9
There was also a good match between IDDM adolescents as a
whole and their non-diabetic sibling controls, with respect to sex,
age, body mass and systolic and diastolic blood pressures (Table
2). The "current" HgbAlc was normal in all sibling controls and
higher overall in the IDDM adolescents (9.0 0.2% vs. 4.9 0.04
in controls, P < 0.0001).
Plasma renin
The mean active renin concentration in plasma showed an
upward trend in the IDDM group with MA but was not signifi-
cantly higher than in the IDDM non-MA group (40.0 4.6 vs.
33.6 4.7 pg/mI, Table 1). When these subgroups were pooled
and the average compared with the renin values of all control
siblings, no significant difference was observed (36.8 3.3 vs.
35.6 1.9 pg/mI, respectively, Table 2).
Plasma prorenin in relation to IDDM and MA
Plasma prorenin was significantly higher in the MA vs. non-MA
group (226.4 13.6 vs. 168.5 10.1 pg/mI, P < 0.0001, Table 1,
Fig. 1). In all but 2 of the 25 matched pairs, the IDDM adolescent
with MA had a higher prorenin value than his/her matched,
non-MA IDDM control. The prorenin concentration in all the
IDDM subjects combined (MA and non-MA IDDM groups, N
50) was also significantly higher than in the combined sibling
control group (N = 39) (197 9.3 vs. 134.0 7.9 pg/mI, P <
0.0001, Table 2). No sex-associated difference in plasma prorenin
was detected within the two IDDM subgroups, or within the
controls, or even between all the males combined and all the
females combined. However, the control siblings matched to the
IDDM subjects with MA (N = 18) had higher plasma prorenin
levels than the corresponding non-MA siblings (N 21, P <
0.0001, Fig. 2).
Correlations between HbAlc, BP and plasma prorenin
There was a weak negative correlation between the plasma
prorenin level in the IDDM adolescents and the "current" HbAlc
level (r =
—0.495, P < 0.01). There were no significant correla-
tions between renin levels and the "current" or "mean" HbAlc
Table 1. Characteristics of subjects with insulin-dependent diabetes
mellitus (IDDM) with microalbuminuria (MA) and without MA
(non-MA)
Results are expressed as mean SCM.
a Non-diabetic reference range 4 to 6%
b AER, albumin excretion rate; P < 0.01
"P < 0.001
Table 2. Characteristics of subjects with insulin-dependent diabetes
mellitus (IDDM) and their non-diabetic siblings
450
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Fig. 1. Comparison of plasma prorenin concentrations in the 25 IDDM
subjects with MA, and their 25 matched non-MA JDDM controls (P <
0.001). The corresponding MA vs. non-MA pairs are joined by the lines.
Results expressed as mean SEM.
a Non-diabetic reference range 4 to 6%
bp <0.0001
10DM
MA
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0
Control for Control for
non-MA MA
Fig. 2. Plasma prorenin concentrations in the 18 control (non-diabetic)
siblings that were matched with the 25 IDDM-MA subjects, are higher than
concentrations in the 21 control (non-diabetic) siblings matched with the 25
IDDM non-MA subjects (P <0.001).
levels, nor between renin or prorenin levels and systolic or
diastolic BP.
Discussion
Early identification of IDDM children who are at risk of
developing diabetic nephropathy is important because it creates
opportunity for medical intervention aimed at arresting insidious
progression of target organ damage. Unfortunately, the tools for
such identification are not readily available. Two promising
approaches, that is, erythrocyte sodium-lithium countertransport
activity and plasma prorenin, are not yet fully validated.
Krolewski et al [19] reported that diabetic adolescents had
accelerated eiythrocyte sodium-lithium countertransport activity
which was greater in patients with microalbuminuria (MA).
Crompton et al [20] confirmed such increased countertransport
activity in diabetic adolescents, relative to their non-diabetic
siblings, but were unable to distinguish those with MA from those
without.
Leutscher and coworkers were first to report high concentra-
tions of plasma prorenin in diabetic patients [3, 4, 21] and to
associate this with developing nephropathy [22, 23]. However,
other workers, notably Franken et al [7, 24], suggest mainly
extrarenal sources for the prorenin, casting doubt upon its impor-
tance as a specific marker of nephropathy.
In an attempt to clarify the prorenin issue, we studied carefully
characterized children with IDDM, and well-matched sibling
controls, using refined laboratory methods. The IDDM subjects
were teenagers with a relatively short duration of disease, thereby
creating expectation of a low incidence and severity of diabetic
complications in this population. The comparison groups were
well-matched, that is, IDDM's with, and without, MA and
IDDM's versus non-diabetic siblings. Both "current" and "mean"
HbAlc values were similar in the IDDM subgroups, suggesting
comparable levels of metabolic control of their diabetes.
Trujillo et al [6] reviewed plasma renin activity (PRA) in
diabetes. They cite several studies which report low, normal, or
high PRA in specified diabetic study groups, for the most part
using conventional methods for PRA determination that depend
on the generation of angiotensin I. Such varying outcomes, based
on different methods, and applied to diverse groups of diabetics,
do not invite detailed comparison with our present data based on
direct radioimmunoassay of renin. We can only report that the
plasma active renin level in our IDDM group with MA tended to
be slightly higher than in the non-MA subgroup, but the difference
was not statistically significant. The same was true when all IDDM
subjects were compared with all control siblings.
In marked contrast, plasma prorenin level in our IDDM
subjects with MA was clearly higher than in subjects without MA.
In addition, in the IDDM subjects, MA and non-MA combined,
the plasma prorenin concentration was significantly higher than in
the control siblings. Of particular interest is the finding that the
control sibling subgroup for IDDM with MA had a significantly
higher plasma prorenin level than the control subgroup for
IDDM, non-MA. This difference could not be attributed to any
detected clinical or laboratory findings. It may, therefore, reflect a
familial predisposition to a higher plasma prorenin level that
precedes overt diabetes. In the non-diabetic state it may be of
little, or no, importance, only becoming so with the development
of IDDM. Anderson et al [25] have recently reported that
elevated plasma prorenin precedes MA and therefore may be a
useful predictor of diabetic nephropathy.
The exclusive association between elevated plasma prorenin
and nephropathy is somewhat puzzling because heinodynamic
changes induced by renal disease associated with arteriolar con-
striction might be expected also to influence renin release. It is
well known that hemodynamic changes due to arteriolar constric-
tion ("micro-Goldblatt clamps") can lower pressure distally, at the
juxtaglomerular apparatus, stimulate the baroceptor mechanism,
and thereby provoke greater renin release. By this mechanism,
renal renin release would be expected to rise as high, or higher,
than prorenin release. Since this is manifestly not the case in our
study, we have to assume that another mechanism could be at play
in the kidney, or that the prorenin comes from non-renal sources
but still serves as a marker of nephropathy because similar
(microvascular?) events are happening simultaneously, both in-
side and outside the kidney.
Franken et al [24] suggest two major possibilities: an increase in
the renal or extrarenal synthesis of prorenin, and/or reduced
clearance of prorenin from the blood. A third possibility involves
reduced conversion of prorenin to renin, be it inside, or outside,
the kidney.
In terms of greater prorenin production by the kidney, Misbin
et al [26] have tried to link autonomic dysfunction in diabetes to
high plasma prorenin. They proposed that this would disturb
adrenergic regulation of renal juxtaglomerular cells and promote
proportionately higher secretion of prorenin. However, Franken
et at [24] argue that none of their patients with elevated plasma
prorenin had overt autonomic neuropathy. They found no asso-
ciation between plasma noradrenaline and prorenin to support
this mechanism.
Franken et a! [7] reported that their patients with end-stage
renal disease and proliferative retinopathy did not have an
elevated renal vein-to-artery ratio for plasma prorenin, despite
their impaired renal plasma flow and an elevated plasma prorenin.
This favors an extrarenal source of the prorenin and they sug-
gested that the eye (affected by diabetic retinopathy) is that source
[27]. Prorenin relative to albumin, and other plasma proteins, was
higher in vitreous fluid from eyes with proliferative diabetic
retinopathy and traction retinal detachment than in eyes of
nondiabetic subjects with spontaneous retinal detachment [28].
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It is difficult to verify the source of prorenin production. In an
older group of IDDM patients with retinal disease Franken et al
[7j excluded the kidneys as the source of prorenin and suggested
it came from the eyes. In this study, we correlated prorenin
concentrations with the presence or absence of incipient nephrop-
athy in a group of well defined adolescents with IDDM. Incipient
nephropathy, as defined by the detection of microalbuminuria,
has been well demonstrated to be a good predictor of those
patients with IDDM, approximately one-third, who will proceed
to frank proteinuria and eventual end-stage renal disease. We did
not correlate prorenin, however, with the presence or absence of
retinopathy; they were relatively young and had had diabetes of
relatively short duration. As would be expected, none had serious
retinopathy defined by the presence of macular edema and
preproliferative or proliferative retinopathy [29]. The presence of
background retinopathy was not felt to be an acceptable measure
of significant eye disease since it does not have the same prog-
nostic significance as microalbuminuria. Specifically, virtually
100% of subjects with IDDM will develop background changes
within about 20 years of onset, yet less than half progress to more
severe sight-threatening retinal lesions [19].
It is tempting to speculate that the earliest observable increase
in plasma prorenin in diabetic subjects might be of predominantly
renal origin, and reflect the beginnings of renal disease, while later
stages of disease might be accompanied by increased release of
predominantly extrarenal prorenin into the plasma. It would
follow that in later stages of diabetes [27, 28], extrarenal prorenin
may predominate in plasma and mask any association between
specifically renal prorenin and nephropathy.
Little is known about the clearance of prorenin and whether
such clearance is exclusively via conversion to renin in the kidney,
or elsewhere. Bryer-Ash, Fraze and Leutscher [30] and Nakamura
et al [31] suggested a reduced rate of conversion of prorenin to
active renin in the kidneys of some diabetic patients. However,
Shimojo et al [32] report that"... it is not clear whether altered
protein metabolism (in diabetes mellitus) is related to (impaired)
conversion from inactive renin to active renin." Sasamura et al
[33] argue against a defect in conversion of inactive renin to active
renin in their patients with diabetic nephropathy. Thus, all
avenues of explanation for elevated plasma prorenin in diabetes
remain unresolved.
Finally, our use of the direct method for renin determination
may be a factor in producing the results we obtained. It avoids any
kinetic variables that can be associated with conventional PRA
determinations and which could be affected by diabetes. These
include possible renin-substrate (angiotensinogen) changes, al-
tered renin reactivity and non-linear generation of angiotensin I,
all of which could affect PRA values reported in the literature, but
not necessarily direct renin values. Our use of a verified direct
renin method [18], and standardized prorenin activation proce-
dures, may have influenced our results relative to others in the
literature.
In conclusion, in a well-characterized group of normotensive
adolescents with IDDM of recent onset, and minimal detectable
complications, the presence of significant MA, suggestive of
incipient nephropathy, correlates well with a rise in plasma
prorenin. This supports previous reports of prorenin as an early
marker of diabetic nephropathy. In contrast, plasma renin con-
centration was normal in our IDDM subjects as a whole, and not
elevated in those with MA. Our data cannot necessarily be
extrapolated to later, more complicated, stages of the disease and
do not rule out the presence of extrarenal prorenin in plasma.
There is, as yet, no adequate physiological/pathophysiological
explanation of the mechanisms responsible for prorenin elevation
in IDDM with MA. In addition, the intriguing finding of raised
prorenin concentrations in the siblings of the IDDM subjects with
MA compared to those without MA, strengthens the possiblity of
a link between diabetic nephropathy and certain genetically
controlled renal hemodynamic factors and warrants further inves-
tigation.
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